Men's Scalp Solution is built around a coherent internal logic — each active serving a defined and non-redundant role in restoring follicular hormonal balance:

Dual-mechanism DHT suppression creates the foundation: Azelaic acid inhibits 5-alpha reductase enzymatically, reducing intrafollicular testosterone-to-DHT conversion. Progesterone independently inhibits 5-alpha reductase through a distinct pathway, providing additive enzymatic DHT suppression. Together they substantially reduce the intrafollicular DHT that drives follicular miniaturization — creating the biochemical environment in which topical testosterone can be delivered without its primary adverse consequence in androgenetically susceptible follicles.

Progesterone's receptor competition provides redundant protection: Beyond enzyme inhibition, progesterone competitively occupies androgen receptors in follicular cells — reducing DHT's ability to activate miniaturization signaling at the receptor level even if residual DHT is present despite enzyme inhibition. This provides a second layer of follicular protection that ensures testosterone's inclusion in the formula is clinically safe within the context of comprehensive DHT suppression.

Testosterone restores physiological androgenic follicular stimulation: With DHT conversion substantially suppressed by dual enzyme inhibition and receptor competition providing additional protection, topically delivered testosterone provides direct androgen receptor stimulation — supporting the androgenic follicular signaling that contributes to growth in androgen-responsive follicles without the miniaturization consequences of DHT-driven receptor activation. This is the mechanism that distinguishes Men's Scalp Solution from simple anti-androgenic approaches.

Liothyronine addresses the thyroid axis independently: T3 delivery to follicular tissue restores thyroid hormone receptor-mediated follicular cycling regulation — supporting anagen initiation, follicular metabolic activity, and keratinocyte gene expression through a biological axis that the androgenic components of this formula cannot reach. Men with a thyroid component to their hair loss — suboptimal tissue-level T3 activity contributing to shortened anagen duration — receive simultaneous anti-androgenic and thyroid-axis support in a single nightly application.

Azelaic acid supports the perifollicular environment: The anti-inflammatory and antioxidant properties of azelaic acid ensure that the follicular tissue receiving hormonal support is in an environment capable of responding productively — reducing the inflammatory and oxidative burden that would otherwise compound follicular damage alongside the hormonal contributors being addressed by the other actives.

With consistent nightly application as directed by your prescribing provider:

Reduced intrafollicular DHT through dual-mechanism 5-alpha reductase inhibition — enzymatic suppression from both azelaic acid and progesterone simultaneously

Follicular androgen receptor protection through progesterone's competitive receptor binding, reducing residual DHT signaling even beyond enzyme inhibition

Restored physiological androgenic follicular stimulation through direct testosterone receptor activity in a DHT-suppressed follicular environment

Improved thyroid hormone-mediated follicular cycling, anagen initiation, and metabolic follicular activity through local T3 delivery

Reduced perifollicular inflammatory and oxidative burden through azelaic acid's anti-inflammatory and antioxidant activity

Preservation of existing hair density in follicles that remain responsive to hormonal support

Support for hair regrowth in areas of early-to-moderate miniaturization

Improved hair shaft caliber and structural quality as follicular metabolic activity is restored across multiple hormonal axes

A biologically comprehensive approach to androgenetic alopecia that addresses hormonal balance — androgenic, progestogenic, and thyroid — rather than uniform androgenic suppression

Results vary by individual, age, pattern and extent of hair loss, baseline hormonal profile, and follicular reserve at treatment initiation. Plan for a minimum six-month treatment course before assessing cosmetic response. Initial reduction in shedding is typically the first sign of treatment effect, preceding visible density improvement. Ongoing nightly application is the clinical expectation — results diminish when treatment is discontinued.

Apply a small amount topically to the affected areas of the scalp at bedtime.

Application Instructions:

Ensure the scalp is clean and dry before application. Evening application after showering — once hair and scalp are fully dry — is ideal, maximizing overnight contact time with follicular tissue.

Part the hair to expose the thinning or affected scalp regions — typically the vertex, crown, and frontal scalp.

Apply a small amount of solution — as directed by your provider — directly to the affected areas using the applicator or dropper, distributing evenly across the treatment zone.

Using the fingertips, thoroughly massage the solution into the scalp with gentle circular motions, ensuring even coverage and promoting absorption into the perifollicular tissue.

Allow to dry fully. Do not rinse. The solution should remain on the scalp overnight.

Wash hands thoroughly immediately after application. This formula contains testosterone and other hormonal actives that can be absorbed through skin contact. Minimize hand contact and wash hands promptly after each application. Women — particularly pregnant women — and children must not contact this solution.

Resume styling or other scalp products only after the solution has fully absorbed.

Bedtime application is strongly preferred — overnight contact maximizes absorption of all four actives and keeps the solution on the scalp undisturbed during peak nocturnal skin repair activity.

If a dose is missed: Apply when remembered on the same day, or resume the regular schedule at the next planned application. Do not double-apply to compensate for a missed dose.

Duration: Plan for a minimum six-month assessment period. Ongoing nightly application is the clinical expectation — hormonal follicular support requires sustained delivery to maintain its effect.

Men's Scalp Solution is a prescription-only compounded medication containing testosterone and other hormonal actives. Full patient counseling and baseline hormonal assessment are required before initiating therapy.

This formula is designed for use in adult men only. Women and children must not use or handle this product.

Contraindications:

Women and children — skin contact prohibited: This formula contains testosterone. Women — particularly pregnant women — and children must not apply, handle, or contact this solution. Testosterone absorbed through skin contact can cause virilization in women and children and developmental harm in male fetuses. Store where women and children cannot access it.

Prostate cancer or PSA elevation: Testosterone and androgenic stimulation are contraindicated in men with known or suspected prostate cancer, or with significantly elevated PSA without urological evaluation. Discuss prostate health history with your provider before initiating therapy.

Breast cancer: Men with a personal history of breast cancer should not use testosterone-containing products without oncological evaluation.

Polycythemia or elevated hematocrit: Testosterone stimulates erythropoiesis — men with polycythemia or significantly elevated hematocrit should discuss this with their provider before initiating.

Active thyroid conditions: Liothyronine delivers biologically active T3 with systemic absorption potential. Men with hyperthyroidism, thyrotoxicosis, cardiac arrhythmia, or significant cardiovascular disease must not use this formula without explicit specialist evaluation.

Known hypersensitivity: Patients with documented allergy to any formula component should not use this product.

Potential Side Effects:

Testosterone-related:

Increased sebum production and acne at or near application sites — androgen receptor stimulation in sebaceous glands; report if significant

Rare systemic androgenic effects from scalp absorption — increased body hair, mood changes, or libido changes — if significant systemic testosterone absorption occurs; more likely with large application areas or compromised scalp barrier; report to provider

PSA changes — testosterone can stimulate prostate tissue; baseline and periodic PSA monitoring is appropriate during therapy

Erythrocytosis — testosterone stimulates red blood cell production; periodic hematocrit monitoring is appropriate with ongoing use

Liothyronine-related:

Rare systemic thyroid effects — palpitations, tachycardia, tremor, anxiety, heat intolerance, insomnia — from scalp absorption; report any cardiovascular or thyroid symptoms promptly

Patients on systemic thyroid medication require thyroid function monitoring after initiating topical liothyronine

Azelaic acid-related:

Mild scalp tingling, itching, or warmth at application — typically during the first one to two weeks; usually transient

Mild scalp dryness or flaking, particularly if used alongside other desiccating scalp products

Progesterone-related:

Mild local scalp sensitivity in patients with progesterone sensitivity

Rare systemic progestogenic effects from significant absorption — drowsiness, mood changes; report if experienced

General:

Transient increased shedding during the first four to eight weeks — follicles transitioning from resting to active growth phase; expected and temporary; consult provider before discontinuing

Contact dermatitis in patients with sensitivity to any formula component or vehicle

Testosterone replacement therapy (TRT): Men on systemic testosterone therapy — injectable, transdermal, or oral — must inform their provider. Combined systemic and topical testosterone exposure requires coordinated clinical management and testosterone monitoring to avoid supraphysiological androgen levels.

5-alpha reductase inhibitors (oral finasteride, dutasteride): Patients on oral 5-alpha reductase inhibitors should inform their provider — combined systemic and topical 5-alpha reductase inhibition requires clinical management to avoid unintended additive DHT suppression.

Systemic thyroid medications: Patients on levothyroxine, liothyronine, or desiccated thyroid hormone must discuss topical liothyronine use with their provider. Combined exposure requires thyroid function monitoring and potential systemic dose adjustment.

Antithyroid medications: Topical T3 may partially counteract antithyroid therapy; discuss with your endocrinologist.

Anticoagulants: Testosterone and thyroid hormones both have potential interactions with anticoagulant therapy — inform all providers of this formula's components.

Beta-blockers and cardiovascular medications: Thyroid hormone can increase cardiac sensitivity; patients on cardiovascular medications should inform their provider of topical liothyronine use.

Insulin and antidiabetic medications: Both testosterone and thyroid hormone affect insulin sensitivity and glucose metabolism; patients on antidiabetic medications should monitor closely and inform their provider.

Other topical scalp treatments: Apply in sequence with adequate absorption time between products. Discuss all concurrent scalp treatments with your provider.

Store at room temperature, 68°F – 77°F (20°C – 25°C), away from direct heat, humidity, and light

Keep container tightly closed between uses

Do not freeze

Keep strictly out of reach of women and children — testosterone in any form must not contact the skin of women or children

Do not use beyond the labeled expiration date

If refrigeration is specified on your label, store accordingly